CellEDIT - CRISPR Cell Line Development Services
Custom CRISPR Cell Line Development Services through direct intra-nuclear delivery.
The journey starts from a single cell
The journey starts from a single cell. The CellEDIT Service can address the need for reliable manufacturing of cell line, with its precision cell line development and engineering services. Based on our unique single-cell transfection technology, we reliably and accurately produce high-quality cell lines with unparalleled control, in 10 weeks. CellEDIT provides custom cell line engineering services using FluidFM patented technology that surpasses conventional methods in delivering CRISPR complexes directly to the nucleus, ensuring high-quality cell line engineering for your research.
This unique workflow significantly reduces the occurrence of off-target effects, achieved by delivering a precise volume of RNP complexes directly into the nucleus of the target cell, while preserving cell viability. Guided by our experts, each project is tailored to your needs—from gRNA design and cell culture methods to gentle yet efficient delivery and personalized quality controls—preserving cell integrity throughout the whole process.
In 10 weeks, we will provide you with knockout monoclonal cell lines suited to your project needs.
Efficient on
Hard-to-transfect cells
Vector-free editing by
intra-nuclear delivery
Reduced Off-Targets
The CellEDIT Service Workflow
When it comes to the commercialization of your product, an effective, high-quality cell line development workflow is essential for your success. It requires a partner that provides you with experience, expertise, and a comprehensive portfolio of products and services — someone who can minimize risks, optimize outcomes and increase your flexibility. The CellEDIT Service by Cytosurge, addresses your needs at every stage of the journey to commercialization, with our complete CRISPR gene engineering outsourcing solution. To offer the most efficient and accurate editing service, preliminary steps involve the onboarding of your cell line and injection optimization; these are crucial prerequisites before initiating the CellEDIT workflow.
Once we have familiarized ourselves with the unique characteristics of your cell line, we can then commence the CellEDIT process. The CellEDIT workflow begins with the injection of CRISPR reagents into a single cell. This meticulous procedure only concludes upon successful acquisition of edited clones, ensuring optimal results tailored to your specific needs.
Your Cells & Edits. Our Service & Expertise
Resources
Deliverables
- gRNA design from the CellEDIT experts.
- Two edited clones & two Wild Type clones that went through the CellEDIT workflow (1 cryovial per clone).
- Full gRNA design report before starting the CellEDIT workflow.
- Full final report including sequencing results of both alleles, monoclonality proof, mycoplasma testing.
On demand:
- Additional clones.
- Off-target analysis & Report.
- Additional information useful for further analysis or publication can be also provided on request.
- Extended quality control available on request.
Educational
Technical
Introduction to CRISPR Knockout Gene Editing with CellEDIT
CellEDIT' CRISPR Cell Line Development Workflow
CellEDIT's Engineered Cell Lines
CRISPR-Engineered U2OS Cell Line
CRISPR-Engineered MDA MB 231 Cell Line
CRISPR-Engineered A549 Cell Line
CRISPR-Edited Hek293 Cell Line
CRISPR-Engineered C2C12 Cell Line
Media & Downloads
On-Demand CellEDIT's CRISPR Cell Line Engineering Webinar
CellEDIT's Application Note n*1 - Introducing the CellEDIT Workflow
CellEDIT's Application Note n*2 - Overcoming the hard-to-transfect cell line hurdle
Case Study - Streamlined U2OS Cell Line Modification with the CellEDIT Service Workflow, featuring our CellEDIT Customer: Dr. Kanstantsin Siniuk.
Open Access Publication featuring CellEDIT: Antony, Justin S., Anabel Migenda Herranz, Tahereh Mohammadian Gol, Susanne Mailand, Paul Monnier, Jennifer Rottenberger, Alicia Roig‐Merino et al. " Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9" Biotechnology Journal 19, no. 4 (2024): 2300505.